Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Jan 12;5(2):124-126.
doi: 10.1016/j.jdcr.2018.11.004. eCollection 2019 Feb.

Linear IgA bullous dermatosis treated with rituximab

Affiliations
Case Reports

Linear IgA bullous dermatosis treated with rituximab

Camille Pinard et al. JAAD Case Rep. .
No abstract available

Keywords: LABD, Linear IgA bullous dermatosis; MMF, mycophenolate mofetil; autoimmune blistering disease; linear IgA bullous dermatosis; rituximab.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Urticarial eruption of the trunk.
Fig 2
Fig 2
Complete remission after 4 infusions of rituximab.

References

    1. Bernard P., Vaillant L., Labeille B. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. Arch Dermatol. 1995;131:48–52. - PubMed
    1. Paul C., Wolkenstein P., Prost C. Drug-induced linear IgA disease: target antigens are heterogeneous. Br J Dermatol. 1997;136:406–411. - PubMed
    1. Albers L.N., Zone J.J., Stoff B.K., Feldman R.J. Rituximab Treatment for recalcitrant dermatitis herpetiformis. JAMA Dermatol. 2017;153:315–318. - PubMed
    1. Lozinski A., Baum S., Sagi L., Volkov A., Trau H., Barzilai A. [Rituximab (Mabthera) for treatment of rare autoimmune bullous skin disorders] Harefuah. 2012;151:562–565. 606. - PubMed
    1. Vodegel R.M., de Jong M.C.J.M., Pas H.H., Jonkman M.F. IgA-mediated epidermolysis bullosa acquisita: two cases and review of the literature. J Am Acad Dermatol. 2002;47:919–925. - PubMed

Publication types